https://ir.opusgtx.com/ https://ir.opusgtx.com/press-releases https://ir.opusgtx.com/events https://ir.opusgtx.com/company-information https://ir.opusgtx.com/company-information/presentations https://ir.opusgtx.com/company-information/contacts https://ir.opusgtx.com/company-information/faq https://ir.opusgtx.com/financial-information https://ir.opusgtx.com/financial-information/financial-results https://ir.opusgtx.com/financial-information/income-statement https://ir.opusgtx.com/financial-information/balance-sheet https://ir.opusgtx.com/financial-information/cash-flow https://ir.opusgtx.com/stock-data/quote-chart https://ir.opusgtx.com/stock-data/historical-data https://ir.opusgtx.com/stock-data/analyst-coverage https://ir.opusgtx.com/sec-filings/all-sec-filings https://ir.opusgtx.com/sec-filings/annual-reports https://ir.opusgtx.com/sec-filings/quarterly-reports https://ir.opusgtx.com/sec-filings/section-16-filings https://ir.opusgtx.com/corporate-governance https://ir.opusgtx.com/corporate-governance/board-committees https://ir.opusgtx.com/corporate-governance/governance-documents https://ir.opusgtx.com/investor-tools/email-alerts https://ir.opusgtx.com/investor-tools/contacts https://ir.opusgtx.com/investor-tools/rss-news-feed https://ir.opusgtx.com/press-releases/detail/523/opus-genetics-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026 2026-03-24T07:00:03-04:00 https://ir.opusgtx.com/press-releases/detail/522/opus-genetics-announces-financial-results-for-full-year-2025-and-provides-corporate-update 2026-03-10T07:00:04-04:00 https://ir.opusgtx.com/press-releases/detail/521/opus-genetics-to-present-at-upcoming-investor-conferences-in-march-2026 2026-03-03T08:00:05-05:00 https://ir.opusgtx.com/press-releases/detail/520/opus-genetics-announces-initial-clinical-data-from-phase-12-opgx-best1-gene-therapy-study-at-the-macula-society-annual-meeting 2026-02-27T10:10:01-05:00 https://ir.opusgtx.com/press-releases/detail/519/opus-genetics-announces-fda-acceptance-of-supplemental-new-drug-application-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia 2026-02-25T06:59:01-05:00 https://ir.opusgtx.com/press-releases/detail/518/opus-genetics-announces-25-million-private-placement 2026-02-13T07:30:01-05:00 https://ir.opusgtx.com/press-releases/detail/517/opus-genetics-to-participate-in-upcoming-medical-and-industry-conferences-in-february-2026 2026-02-02T08:00:07-05:00 https://ir.opusgtx.com/press-releases/detail/516/opus-genetics-launches-gene-therapy-clinical-trial-for-mertk-related-retinitis-pigmentosa 2026-01-27T07:00:03-05:00 https://ir.opusgtx.com/press-releases/detail/515/opus-genetics-highlights-2025-progress-and-upcoming-2026-catalysts 2026-01-08T07:00:07-05:00 https://ir.opusgtx.com/press-releases/detail/514/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-12-16T16:01:01-05:00 https://ir.opusgtx.com/press-releases/detail/513/opus-genetics-to-present-at-the-j-p-morgan-2026-healthcare-conference 2025-12-11T07:00:08-05:00 https://ir.opusgtx.com/press-releases/detail/512/opus-genetics-announces-positive-recommendation-from-independent-data-monitoring-committee-for-phase-12-trial-in-best-disease 2025-12-09T07:00:02-05:00 https://ir.opusgtx.com/press-releases/detail/511/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-12-02T16:01:01-05:00 https://ir.opusgtx.com/press-releases/detail/510/opus-genetics-to-participate-in-upcoming-investment-conferences 2025-11-20T08:00:14-05:00 https://ir.opusgtx.com/press-releases/detail/509/opus-genetics-announces-dosing-of-first-participant-in-opgx-best1-phase-12-gene-therapy-clinical-trial-for-best-disease 2025-11-13T07:00:02-05:00 https://ir.opusgtx.com/press-releases/detail/508/opus-genetics-announces-financial-results-for-third-quarter-2025-and-provides-corporate-update 2025-11-12T07:00:13-05:00 https://ir.opusgtx.com/press-releases/detail/507/opus-genetics-announces-successful-fda-meeting-supporting-advancement-of-opgx-lca5-toward-pivotal-trial-for-lca5-related-inherited-retinal-disease 2025-11-06T07:00:42-05:00 https://ir.opusgtx.com/press-releases/detail/506/opus-genetics-announces-23-million-registered-direct-offering 2025-11-06T07:00:12-05:00 https://ir.opusgtx.com/press-releases/detail/505/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-11-04T16:01:01-05:00 https://ir.opusgtx.com/press-releases/detail/504/opus-genetics-featured-on-good-morning-america-spotlighting-breakthrough-gene-therapy-restoring-sight-in-patients-with-inherited-blindness 2025-11-03T08:00:20-05:00 https://ir.opusgtx.com/press-releases/detail/503/opus-genetics-to-participate-in-chardans-9th-annual-genetic-medicines-conference 2025-10-14T08:00:08-04:00 https://ir.opusgtx.com/press-releases/detail/502/opus-genetics-to-present-at-upcoming-medical-and-industry-conferences-in-october-2025 2025-10-02T08:00:03-04:00 https://ir.opusgtx.com/press-releases/detail/501/opus-genetics-reports-positive-pediatric-data-from-opgx-lca5-phase-12-trial-in-leber-congenital-amaurosis-type-5-lca5 2025-09-30T07:00:06-04:00 https://ir.opusgtx.com/press-releases/detail/500/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-09-12T08:00:02-04:00 https://ir.opusgtx.com/press-releases/detail/499/opus-genetics-doses-first-patient-in-pivotal-lynx-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-0-75-in-keratorefractive-patients-with-visual-disturbances-under-mesopic-low-contrast-conditions 2025-09-04T08:00:18-04:00 https://ir.opusgtx.com/press-releases/detail/498/opus-genetics-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference 2025-09-03T08:00:02-04:00 https://ir.opusgtx.com/press-releases/detail/497/opus-genetics-appoints-rob-gagnon-as-chief-financial-officer 2025-09-02T08:00:15-04:00 https://ir.opusgtx.com/press-releases/detail/496/opus-genetics-inherited-retinal-disease-programs-featured-at-medical-and-industry-conferences-in-september 2025-08-27T08:00:21-04:00 https://ir.opusgtx.com/press-releases/detail/495/opus-genetics-announces-fda-clearance-of-ind-application-for-gene-therapy-candidate-opgx-best1 2025-08-18T08:00:02-04:00 https://ir.opusgtx.com/press-releases/detail/494/opus-genetics-announces-financial-results-forsecond-quarter-2025-and-provides-corporate-update 2025-08-13T16:30:02-04:00 https://ir.opusgtx.com/press-releases/detail/493/opus-genetics-to-participate-in-the-h-c-wainwright-5th-annual-ophthalmology-virtual-conference 2025-08-05T08:00:33-04:00 https://ir.opusgtx.com/press-releases/detail/492/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapyfor-inherited-childhood-blindness 2025-07-23T08:00:12-04:00 https://ir.opusgtx.com/press-releases/detail/491/opus-genetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-07-03T16:30:01-04:00 https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia 2025-06-26T06:55:01-04:00 https://ir.opusgtx.com/press-releases/detail/489/opus-genetics-awarded-non-dilutive-funding-from-the-rd-fund-to-support-preclinical-development-of-opgx-mertk-program 2025-06-23T08:00:08-04:00 https://ir.opusgtx.com/press-releases/detail/488/opus-genetics-announces-lynx-2-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-in-keratorefractive-patients-with-visual-disturbances-under-mesopic-low-contrast-conditions 2025-06-02T08:00:08-04:00 https://ir.opusgtx.com/press-releases/detail/487/opus-genetics-announces-financial-results-for-first-quarter-2025-and-provides-corporate-update 2025-05-15T08:00:20-04:00 https://ir.opusgtx.com/press-releases/detail/486/opus-genetics-announces-presentations-on-inherited-retinal-disease-programs-at-medical-conferences-in-may 2025-05-12T08:00:05-04:00 https://ir.opusgtx.com/press-releases/detail/485/opus-genetics-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-opgx-lca5-gene-therapy-candidate 2025-05-06T08:00:04-04:00 https://ir.opusgtx.com/press-releases/detail/484/opus-genetics-announces-presentation-of-opgx-lca5-gene-therapy-data-at-arvo-12-month-phase-12-results-support-potential-to-restore-to-meaningful-vision 2025-05-05T08:00:22-04:00 https://ir.opusgtx.com/press-releases/detail/483/opus-genetics-announces-one-month-clinical-data-from-pediatric-patient-in-phase-12-trial-of-opgx-lca5-gene-therapy-in-inherited-retinal-diseases 2025-04-08T08:00:06-04:00 https://ir.opusgtx.com/press-releases/detail/482/opus-genetics-files-definitive-proxy-statement-and-sends-letter-to-stockholders-highlighting-the-companys-transformation-and-progress 2025-04-07T08:00:06-04:00 https://ir.opusgtx.com/press-releases/detail/481/opus-genetics-to-participate-in-upcoming-investor-conference-in-april 2025-04-02T08:00:08-04:00 https://ir.opusgtx.com/press-releases/detail/480/opus-genetics-announces-financial-results-for-full-year-2024 2025-03-31T08:20:27-04:00 https://ir.opusgtx.com/press-releases/detail/479/opus-genetics-announces-presentation-on-phentolamine-ophthalmic-solution-0-75-in-dim-light-disturbances-at-world-cornea-congress-ix 2025-03-21T09:30:24-04:00 https://ir.opusgtx.com/press-releases/detail/478/opus-genetics-announces-pricing-of-public-offering-and-concurrent-private-placement-with-proceeds-of-over-20-million 2025-03-21T09:11:49-04:00 https://ir.opusgtx.com/press-releases/detail/477/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-03-19T15:56:20-04:00 https://ir.opusgtx.com/press-releases/detail/476/opus-genetics-announces-presentations-at-association-for-research-in-vision-and-ophthalmologyarvo-2025-meeting 2025-03-05T08:00:40-05:00 https://ir.opusgtx.com/press-releases/detail/475/opus-genetics-announces-fda-fast-track-and-enrollment-updates-for-phentolamine-ophthalmic-solution-0-75-programs 2025-02-26T08:00:06-05:00 https://ir.opusgtx.com/press-releases/detail/474/opus-genetics-announces-updates-on-opgx-lca5-clinical-program 2025-02-18T07:30:11-05:00 https://ir.opusgtx.com/press-releases/detail/473/opus-genetics-receives-fda-agreement-under-special-protocol-assessment-for-phase-3-trial-of-apx3330-in-diabetic-retinopathy 2024-12-19T08:00:07-05:00 https://ir.opusgtx.com/press-releases/detail/472/opus-genetics-to-host-virtual-kol-event-on-opgx-lca5-as-a-treatment-for-lca5-associated-inherited-retinal-disease-on-december-11-2024 2024-12-03T08:19:33-05:00 https://ir.opusgtx.com/press-releases/detail/471/opus-genetics-announces-financial-results-for-third-quarter-2024-and-provides-corporate-update 2024-11-12T09:57:39-05:00 https://ir.opusgtx.com/press-releases/detail/470/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-11-12T09:57:14-05:00 https://ir.opusgtx.com/press-releases/detail/469/ocuphire-pharma-announces-acquisition-of-opus-genetics 2024-10-22T16:05:04-04:00 https://ir.opusgtx.com/press-releases/detail/443/ocuphire-pharma-announces-publication-of-full-phase-3-results-of-phentolamine-ophthalmic-solution-0-75for-pharmacologically-induced-mydriasis-in-ophthalmology 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/442/update-ocuphire-pharma-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-0-75-for-presbyopia 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/467/ocuphire-pharma-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-0-75-for-presbyopia 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/444/opus-genetics-receives-rare-pediatric-disease-designation-from-the-u-s-fda-for-ocular-gene-therapy-opgx-lca5-to-treat-rare-inherited-retinal-disease-lca5 2024-10-21T13:39:10-04:00 https://ir.opusgtx.com/press-releases/detail/440/ocuphire-pharma-announces-financial-results-for-second-quarter-2024-and-provides-corporate-update 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/439/ocuphire-pharma-to-present-at-two-investor-conferences-in-august 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/438/ocuphire-pharma-to-highlight-apx3330-for-diabetic-retinopathy-at-two-scientific-meetings-in-july 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/445/opus-genetics-announces-1-7-million-in-project-based-funding-from-the-foundation-fighting-blindness-to-support-two-preclinical-programs 2024-10-21T13:39:10-04:00 https://ir.opusgtx.com/press-releases/detail/437/ocuphire-pharma-announces-presentations-on-the-development-of-apx3330-for-diabetic-retinopathy-at-retina-meetings-in-june 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/436/ocuphire-pharma-announces-financial-results-for-first-quarter-2024-and-provides-corporate-update 2024-10-21T13:40:02-04:00 https://ir.opusgtx.com/press-releases/detail/435/ocuphire-pharma-announces-presentation-on-apx3330-at-the-arvo-2024-annual-meeting 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/434/ocuphire-pharma-to-present-at-the-aegis-virtual-conference 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/468/ocuphire-pharma-announces-apx3330-presentation-at-arvo-2024-annual-meeting 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/433/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-ophthalmic-solution-0-75-ps-for-the-treatment-of-decreased-visual-acuity-under-low-light-conditions-following-keratorefractive-surgery 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/432/ocuphire-announces-the-u-s-commercial-launch-of-ryzumvl-phentolamine-ophthalmic-solution-0-75-by-its-partner-viatris 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/446/opus-genetics-announces-completion-of-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-rare-inherited-retinal-disease-lca5 2024-10-21T13:39:11-04:00 https://ir.opusgtx.com/press-releases/detail/431/ocuphire-pharma-announces-financial-results-for-fourth-quarter-and-full-year-2023-and-provides-corporate-update 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/430/ocuphire-pharma-to-present-in-the-bio-ceo-investor-conference 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/429/ocuphire-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:03-04:00 https://ir.opusgtx.com/press-releases/detail/428/ocuphire-pharma-strengthens-leadership-team-with-key-appointments 2024-10-21T13:40:04-04:00 https://ir.opusgtx.com/press-releases/detail/427/ocuphire-pharma-announces-presentation-on-apx3330-at-the-annual-angiogenesis-exudation-and-degeneration-2024-conference 2024-10-21T13:40:04-04:00 https://ir.opusgtx.com/press-releases/detail/426/ocuphire-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:04-04:00 https://ir.opusgtx.com/press-releases/detail/425/ocuphire-pharma-receives-fda-agreement-under-special-protocol-assessment-for-lynx-2-phase-3-trial-of-phentolamine-ophthalmic-solution-for-the-treatment-of-decreased-visual-acuity-under-dim-mesopic-light-conditions 2024-10-21T13:40:04-04:00 https://ir.opusgtx.com/press-releases/detail/424/ocuphire-pharma-announces-presentation-at-ophthalmology-innovation-summit-ois-xiii 2024-10-21T13:40:04-04:00 https://ir.opusgtx.com/press-releases/detail/423/ocuphire-pharma-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:04-04:00 https://ir.opusgtx.com/press-releases/detail/422/ocuphire-pharma-announces-appointment-of-joseph-schachle-m-b-a-as-chief-operating-officer 2024-10-21T13:40:04-04:00 https://ir.opusgtx.com/press-releases/detail/421/ocuphire-pharma-announces-financial-results-for-third-quarter-2023-and-provides-corporate-update 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/447/new-preliminary-clinical-data-on-potential-of-opus-aav-based-gene-therapy-for-rare-inherited-retinal-disease-to-be-presented-at-the-american-academy-of-ophthalmology-annual-conference-2023 2024-10-21T13:39:11-04:00 https://ir.opusgtx.com/press-releases/detail/420/ocuphire-pharma-announces-successful-end-of-phase-2-meeting-with-fda-for-oral-apx3330-in-diabetic-retinopathy 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/419/ocuphire-pharma-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/418/ocuphire-pharma-announces-appointment-of-george-magrath-m-d-m-b-a-m-s-as-chief-executive-officer-and-director 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/417/ocuphire-pharma-to-present-at-aao-2023-and-eyecelerator-retina-showcase 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/416/ocuphire-pharma-to-present-at-euretina-and-retina-society-conferences-in-october 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/415/ocuphire-pharma-and-viatris-announce-fda-approval-of-ryzumvi-phentolamine-ophthalmic-solution-0-75-eye-drops-for-the-treatment-of-pharmacologically-induced-mydriasis-produced-by-adrenergic-agonists-e-g-phenylephrine-or-parasympatholytic-e-g-tropicamide-agents 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/414/ocuphire-pharma-to-participate-in-three-upcoming-investment-bank-conferences 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/413/ocuphire-pharma-to-present-at-escrs-2023-and-modlive-conferences-in-september 2024-10-21T13:40:05-04:00 https://ir.opusgtx.com/press-releases/detail/448/opus-genetics-announces-first-patient-dosed-in-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-rare-inherited-retinal-disease-lca5 2024-10-21T13:39:11-04:00 https://ir.opusgtx.com/press-releases/detail/412/abstract-on-zeta-1-study-of-apx3330-receives-award-at-women-in-ophthalmology-wio-summer-symposium 2024-10-21T13:40:06-04:00 https://ir.opusgtx.com/press-releases/detail/411/ocuphire-pharma-announces-financial-results-for-second-quarter-2023-and-provides-corporate-update 2024-10-21T13:40:06-04:00 https://ir.opusgtx.com/press-releases/detail/410/ocuphire-pharma-to-present-at-the-canaccord-43rd-annual-growth-conference-and-the-h-c-wainwright-ophthalmology-conference-in-august 2024-10-21T13:40:06-04:00 https://ir.opusgtx.com/press-releases/detail/409/ocuphire-to-present-at-american-society-of-retina-specialists-annual-meeting-and-ois-retina-innovation-summit 2024-10-21T13:40:06-04:00 https://ir.opusgtx.com/press-releases/detail/408/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:06-04:00 https://ir.opusgtx.com/press-releases/detail/407/ocuphire-presents-apx3330-zeta-1-clinical-data-in-late-breaker-session-at-the-american-diabetes-associations-annual-conference 2024-10-21T13:40:06-04:00 https://ir.opusgtx.com/press-releases/detail/406/ocuphire-announces-late-breaking-presentation-on-apx3330-zeta-1-clinical-data-at-american-diabetes-association-annual-conference 2024-10-21T13:40:06-04:00 https://ir.opusgtx.com/press-releases/detail/405/ocuphire-presents-apx3330-zeta-1-data-at-clinical-trials-at-the-summit-cts-2023 2024-10-21T13:40:07-04:00 https://ir.opusgtx.com/press-releases/detail/404/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:07-04:00 https://ir.opusgtx.com/press-releases/detail/403/ocuphire-pharma-announces-financial-results-for-first-quarter-2023-and-provides-corporate-update 2024-10-21T13:40:07-04:00 https://ir.opusgtx.com/press-releases/detail/402/ocuphire-announces-apx3330-and-nyxol-data-presentations-at-ascrs-2023-and-eyecelerator 2024-10-21T13:40:07-04:00 https://ir.opusgtx.com/press-releases/detail/401/ocuphire-provides-corporate-update-and-reiterates-previous-guidance-on-clinical-programs 2024-10-21T13:40:08-04:00 https://ir.opusgtx.com/press-releases/detail/400/ocuphire-appoints-rick-rodgers-as-interim-chief-executive-officer 2024-10-21T13:40:08-04:00 https://ir.opusgtx.com/press-releases/detail/399/ocuphire-pharma-announces-financial-results-for-fourth-quarter-and-year-ended-2022-and-provides-corporate-update 2024-10-21T13:40:08-04:00 https://ir.opusgtx.com/press-releases/detail/398/ocuphire-announces-apx3330-and-nyxol-data-presentations-at-arvo-2023-annual-meeting 2024-10-21T13:40:08-04:00 https://ir.opusgtx.com/press-releases/detail/397/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings 2024-10-21T13:40:08-04:00 https://ir.opusgtx.com/press-releases/detail/396/ocuphire-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-of-september-28-2023-for-nyxol-eye-drops-for-reversal-of-mydriasis 2024-10-21T13:40:08-04:00 https://ir.opusgtx.com/press-releases/detail/395/ocuphire-announces-topline-results-from-zeta-1-phase-2-trial-of-oral-apx3330-in-diabetic-retinopathy-and-plans-for-end-of-phase-2-meeting-with-fda 2024-10-21T13:40:09-04:00 https://ir.opusgtx.com/press-releases/detail/394/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia 2024-10-21T13:40:09-04:00 https://ir.opusgtx.com/press-releases/detail/449/opus-genetics-announces-acquisition-of-the-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases 2024-10-21T13:39:11-04:00 https://ir.opusgtx.com/press-releases/detail/393/ocuphire-pharma-announces-submission-of-new-drug-application-to-fda-for-nyxol-eye-drops-for-reversal-of-mydriasis 2024-10-21T13:40:09-04:00 https://ir.opusgtx.com/press-releases/detail/450/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candidate-intended-for-the-treatment-of-rare-inherited-retinal-disease-lca5 2024-10-21T13:39:11-04:00 https://ir.opusgtx.com/press-releases/detail/392/ocuphire-to-present-at-five-upcoming-investorindustry-conferences 2024-10-21T13:40:09-04:00 https://ir.opusgtx.com/press-releases/detail/451/opus-genetics-sponsors-uni-rare-natural-history-study-for-people-with-inherited-retinal-diseases 2024-10-21T13:39:12-04:00 https://ir.opusgtx.com/press-releases/detail/391/ocuphire-pharma-enters-into-a-global-license-agreement-for-development-and-commercialization-of-nyxol-eye-drops-for-reversal-of-mydriasis-presbyopia-and-night-vision-disturbances 2024-10-21T13:40:09-04:00 https://ir.opusgtx.com/press-releases/detail/390/ocuphire-pharma-announces-financial-results-for-third-quarter-2022-and-provides-corporate-update 2024-10-21T13:40:09-04:00 https://ir.opusgtx.com/press-releases/detail/389/ocuphire-announces-peer-reviewed-publication-in-bmc-ophthalmology-for-nyxol-and-strategic-partnership-with-american-society-of-ophthalmic-administrators-asoa 2024-10-21T13:40:10-04:00 https://ir.opusgtx.com/press-releases/detail/388/ocuphire-announces-six-poster-presentations-on-nyxol-and-apx3330-at-the-american-academy-of-optometry-annual-meeting 2024-10-21T13:40:10-04:00 https://ir.opusgtx.com/press-releases/detail/387/ocuphire-pharma-to-present-at-the-microcap-rodeo-windy-city-roundup-2022-conference 2024-10-21T13:40:10-04:00 https://ir.opusgtx.com/press-releases/detail/386/ocuphire-pharma-hosting-key-opinion-leader-event-on-oral-apx3330-for-diabetic-eye-disease 2024-10-21T13:40:10-04:00 https://ir.opusgtx.com/press-releases/detail/385/ocuphire-expands-medical-advisory-board-with-seven-new-kols-and-strengthens-leadership-team 2024-10-21T13:40:10-04:00 https://ir.opusgtx.com/press-releases/detail/452/opus-genetics-expands-board-of-directors-with-appointment-of-global-ophthalmology-leader-dr-adrienne-graves 2024-10-21T13:39:12-04:00 https://ir.opusgtx.com/press-releases/detail/384/ocuphire-announces-upcoming-presentations-at-european-forum-2022-eyeceleratoraao-2022-and-the-american-academy-of-ophthalmology-2022-annual-meeting 2024-10-21T13:40:10-04:00 https://ir.opusgtx.com/press-releases/detail/453/opus-genetics-leadership-to-present-at-3rd-annual-gene-therapy-for-ophthalmic-disorders-conference 2024-10-21T13:39:12-04:00 https://ir.opusgtx.com/press-releases/detail/383/ocuphire-pharma-receives-pdfua-fee-waiver-for-nyxol-new-drug-application-from-fda 2024-10-21T13:40:10-04:00 https://ir.opusgtx.com/press-releases/detail/382/ocuphire-pharma-announces-last-patient-completes-final-visit-in-zeta-1-phase-2b-24-week-trial-of-oral-apx3330-in-diabetic-retinopathy 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/381/ocuphire-pharma-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/454/opus-genetics-hosts-inaugural-patient-advocacy-outreach-webinar-on-inherited-retinal-diseases 2024-10-21T13:39:12-04:00 https://ir.opusgtx.com/press-releases/detail/380/ocuphire-pharma-announces-financial-results-for-the-second-quarter-2022-and-provides-corporate-update 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/379/ocuphire-pharma-announces-upcoming-presentations-at-two-conferences-in-august 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/378/ocuphire-extends-u-s-patent-protection-for-late-stage-drug-candidate-nyxol-for-reversal-of-mydriasis-by-five-more-years-into-2039-with-new-patent-issuance 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/455/opus-genetics-expands-its-leadership-team 2024-10-21T13:39:12-04:00 https://ir.opusgtx.com/press-releases/detail/456/opus-genetics-to-present-at-ois-retina-innovation-summit-2022 2024-10-21T13:39:12-04:00 https://ir.opusgtx.com/press-releases/detail/377/ocuphire-announces-late-breaking-paper-for-nyxol-for-reversal-of-dilation-indication-at-annual-asrs-meeting-and-five-more-presentations-at-conferences-in-july 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/376/ocuphire-granted-new-u-s-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics-and-announces-new-peer-reviewed-apx3330-publication 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/457/opus-genetics-appoints-ben-yerxa-ph-d-as-permanent-chief-executive-officer 2024-10-21T13:39:12-04:00 https://ir.opusgtx.com/press-releases/detail/375/ocuphire-to-present-new-interim-masked-safety-data-for-oral-apx3330-in-diabetics-at-annual-macula-society-meeting 2024-10-21T13:40:11-04:00 https://ir.opusgtx.com/press-releases/detail/374/ocuphire-announces-positive-topline-results-from-lynx-1-phase-3-trial-evaluating-nyxol-eye-drops-for-night-vision-disturbances 2024-10-21T13:40:12-04:00 https://ir.opusgtx.com/press-releases/detail/373/ocuphire-pharma-announces-financial-results-for-first-quarter-2022-and-provides-corporate-update 2024-10-21T13:40:12-04:00 https://ir.opusgtx.com/press-releases/detail/458/opus-genetics-appoints-jennifer-hunt-chief-development-officer 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/372/ocuphire-pharma-announces-upcoming-presentations-at-the-retina-world-congress-clinical-trials-at-the-summit-and-the-h-c-wainwright-global-investment-conference 2024-10-21T13:40:12-04:00 https://ir.opusgtx.com/press-releases/detail/459/opus-genetics-announces-promising-new-data-highlighting-potential-of-aav-based-gene-therapies-for-the-treatment-of-rare-inherited-retinal-diseases 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/460/new-data-on-potential-of-opus-aav-based-gene-therapies-for-rare-inherited-retinal-diseases-to-be-presented-at-association-for-research-in-vision-and-ophthalmology-annual-meeting-2022 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/371/ocuphire-completes-last-clinical-trial-supporting-the-planned-2022-nda-submission-with-the-announcement-of-positive-results-from-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis 2024-10-21T13:40:12-04:00 https://ir.opusgtx.com/press-releases/detail/370/ocuphire-announces-upcoming-clinical-presentations-at-arvo-2022-medical-meeting-and-modlive-2022 2024-10-21T13:40:12-04:00 https://ir.opusgtx.com/press-releases/detail/461/opus-enters-strategic-collaboration-with-resilience-for-aav-based-gene-therapy-development-and-manufacturing-for-inherited-retinal-diseases 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/368/ocuphire-pharma-to-present-at-wet-amd-dme-drug-development-summit-in-boston-ma 2024-10-21T13:40:12-04:00 https://ir.opusgtx.com/press-releases/detail/367/ocuphire-announces-positive-topline-results-from-mira-3-phase-3-fda-registration-trial-for-nyxol-in-the-reversal-of-mydriasis 2024-10-21T13:40:12-04:00 https://ir.opusgtx.com/press-releases/detail/366/ocuphire-announces-financial-results-for-the-fourth-quarter-and-year-ended-december-31-2021-and-provides-corporate-update 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/365/ocuphire-completes-enrollment-of-over-100-subjects-in-24-week-zeta-1-phase-2b-trial-of-oral-apx3330-for-the-treatment-of-diabetic-retinopathy 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/364/ocuphire-pharma-to-present-at-oppenheimer-annual-healthcare-conference 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/363/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/462/opus-genetics-appoints-brian-leising-vice-president-manufacturing 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/362/ocuphire-completes-enrollment-in-mira-3-pivotal-phase-3-clinical-trial-for-nyxol-in-rm-and-announces-two-upcoming-medical-conference-presentations 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/361/ocuphire-presenting-new-data-and-updates-on-apx3330-and-nyxol-clinical-programs-at-virtual-investor-rd-day 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/360/ocuphire-to-host-virtual-investor-rd-day-on-january-31st 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/359/ocuphire-provides-corporate-update-announcing-enrollment-completion-of-phase-3-nyxol-trial-enrollment-initiation-of-nyxol-pediatric-trial-and-an-investor-rd-day-in-january 2024-10-21T13:40:13-04:00 https://ir.opusgtx.com/press-releases/detail/358/ocuphire-expands-prestigious-medical-advisory-board-with-six-new-kols-to-support-advancement-of-late-stage-ophthalmic-assets-nyxol-and-apx3330 2024-10-21T13:40:14-04:00 https://ir.opusgtx.com/press-releases/detail/357/ocuphire-announces-enrollment-of-first-patients-in-second-phase-3-pivotal-trial-mira-3-for-nyxol-in-reversal-of-mydriasis-rm 2024-10-21T13:40:14-04:00 https://ir.opusgtx.com/press-releases/detail/356/ocuphire-announces-financial-results-for-the-third-quarter-2021-and-provides-corporate-update 2024-10-21T13:40:14-04:00 https://ir.opusgtx.com/press-releases/detail/463/opus-genetics-announces-agreement-with-massachusetts-eye-and-ear-and-harvard-medical-school-to-license-third-program-for-inherited-retinal-disease 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/464/opus-genetics-announces-presence-at-eyeceleratoraao-2021 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/355/ocuphire-invited-to-present-clinical-data-on-nyxol-and-apx3330-at-the-american-academy-of-ophthalmology-2021-annual-meeting-and-eyeceleratoraao-meeting 2024-10-21T13:40:14-04:00 https://ir.opusgtx.com/press-releases/detail/465/opus-genetics-announces-two-key-leadership-appointments 2024-10-21T13:39:13-04:00 https://ir.opusgtx.com/press-releases/detail/354/ocuphire-announces-publications-featuring-the-ref-1-protein-a-transcription-factor-regulator-as-a-novel-therapeutic-target-for-the-treatment-of-neovascular-retinal-diseases 2024-10-21T13:40:14-04:00 https://ir.opusgtx.com/press-releases/detail/353/ocuphires-clinical-phase-2b-oral-drug-candidate-apx3330-for-retina-to-be-featured-at-the-ois-retinaasrs-and-asrs-2021-annual-meeting 2024-10-21T13:40:14-04:00 https://ir.opusgtx.com/press-releases/detail/352/ocuphire-pharma-presenting-at-three-upcominghealthcare-conferences-this-fall 2024-10-21T13:40:15-04:00 https://ir.opusgtx.com/press-releases/detail/466/rd-fund-launches-opus-genetics-with-19m-seed-funding-to-advance-gene-therapy-treatments-for-blinding-conditions 2024-10-21T13:39:14-04:00 https://ir.opusgtx.com/press-releases/detail/351/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:15-04:00 https://ir.opusgtx.com/press-releases/detail/350/ocuphire-pharma-presenting-at-four-conferences-in-september 2024-10-21T13:40:15-04:00 https://ir.opusgtx.com/press-releases/detail/349/ocuphire-announces-financial-results-for-the-second-quarter-2021-and-provides-corporate-update 2024-10-21T13:40:15-04:00 https://ir.opusgtx.com/press-releases/detail/348/ocuphire-pharma-presenting-at-two-conferences-in-august 2024-10-21T13:40:15-04:00 https://ir.opusgtx.com/press-releases/detail/347/ocuphire-announces-publication-in-the-journal-of-cellular-signaling-featuring-its-oral-ref-1-inhibitor-apx3330-in-phase-2-trial-for-the-treatment-of-retinal-disease 2024-10-21T13:40:16-04:00 https://ir.opusgtx.com/press-releases/detail/346/ocuphire-selected-to-present-at-multiple-ophthalmic-conferences-in-july 2024-10-21T13:40:16-04:00 https://ir.opusgtx.com/press-releases/detail/345/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:16-04:00 https://ir.opusgtx.com/press-releases/detail/344/ocuphires-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints 2024-10-21T13:40:16-04:00 https://ir.opusgtx.com/press-releases/detail/342/ocuphire-announces-addition-to-the-russell-microcap-index 2024-10-21T13:40:16-04:00 https://ir.opusgtx.com/press-releases/detail/341/ocuphire-announces-closing-of-15-million-registered-direct-offering-priced-at-the-market 2024-10-21T13:40:16-04:00 https://ir.opusgtx.com/press-releases/detail/340/ocuphire-announces-appointment-of-jay-s-pepose-m-d-ph-d-to-its-board-of-directors 2024-10-21T13:40:16-04:00 https://ir.opusgtx.com/press-releases/detail/339/ocuphire-announces-15-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2024-10-21T13:40:17-04:00 https://ir.opusgtx.com/press-releases/detail/338/ocuphire-to-host-key-opinion-leader-event-on-nyxol-as-a-potential-new-treatment-option-for-reversing-pharmacologically-induced-mydriasis 2024-10-21T13:40:17-04:00 https://ir.opusgtx.com/press-releases/detail/337/ocuphire-granted-two-new-u-s-patents-covering-late-stage-drug-candidate-nyxol-including-for-the-treatment-of-presbyopia 2024-10-21T13:40:17-04:00 https://ir.opusgtx.com/press-releases/detail/336/ocuphire-completes-enrollmentinvega-1-phase-2-clinical-trial-investigating-nyxol-in-combination-with-low-dose-pilocarpine-for-treatment-of-presbyopia 2024-10-21T13:40:17-04:00 https://ir.opusgtx.com/press-releases/detail/335/ocuphire-announces-financial-results-for-the-first-quarter-2021-and-provides-corporate-update 2024-10-21T13:40:18-04:00 https://ir.opusgtx.com/press-releases/detail/334/ocuphires-apx3330-for-retinal-diseases-to-be-presented-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-virtual-annual-meeting 2024-10-21T13:40:18-04:00 https://ir.opusgtx.com/press-releases/detail/333/ocuphire-initiates-zeta-1-phase-2-clinical-trial-investigating-apx3330-in-diabetic-retinopathy 2024-10-21T13:40:18-04:00 https://ir.opusgtx.com/press-releases/detail/332/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-10-21T13:40:18-04:00 https://ir.opusgtx.com/press-releases/detail/331/ocuphire-announces-mira-2-phase-3-registration-trial-for-the-reversal-of-mydriasis-meets-primary-endpoint 2024-10-21T13:40:18-04:00 https://ir.opusgtx.com/press-releases/detail/330/ocuphire-announces-financial-results-for-the-full-year-2020-and-provides-corporate-update 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/329/ocuphire-announces-publication-of-mira-1-phase-2b-results-in-optometry-and-visual-science-demonstrating-reduction-of-pharmacologically-induced-mydriasis-by-nyxol 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/328/ocuphire-to-participate-in-march-investor-conferences 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/327/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/326/ocuphire-to-participate-in-the-2021-bio-ceo-investor-conference-and-cantor-fitzgeralds-panel-on-eyeing-key-events-in-the-ophthalmology-space-in-2021 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/325/ocuphire-announces-publication-of-orion-1-phase-2-results-for-nyxol-in-clinical-ophthalmology-and-presentation-at-the-january-ois-presbyopia-innovation-showcase 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/324/ocuphire-completes-enrollment-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-reversal-of-mydriasis 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/323/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/322/ocuphire-to-present-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event-in-early-january-2021 2024-10-21T13:40:19-04:00 https://ir.opusgtx.com/press-releases/detail/321/ocuphire-to-be-featured-in-cantor-fitzgerald-fireside-chat-with-equity-research-analyst-kristen-kluska 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/320/ocuphire-pharma-announces-first-patient-enrolled-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-reversal-of-mydriasis 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/319/ocuphire-pharma-announces-expansion-of-global-patents-for-nyxol-and-1-7-million-nih-grants-for-apx3330-program 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/318/ocuphire-pharma-announces-two-publications-supporting-the-apx3330-program 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/317/ocuphire-to-participate-in-upcoming-virtual-hcw-conference-in-november 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/315/industry-veteran-susan-benton-joins-the-ocuphire-pharma-board-of-directors 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/314/ocuphire-pharma-completes-transactions-and-begins-trading-on-nasdaq-as-ocup 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/313/rexahn-pharmaceuticals-announces-expected-effectiveness-of-reverse-stock-split-and-merger-transaction-with-ocuphire-pharma 2024-10-21T13:39:32-04:00 https://ir.opusgtx.com/press-releases/detail/312/ocuphire-pharma-to-host-key-opinion-leader-event-on-nyxol-and-apx3330 2024-10-21T13:40:20-04:00 https://ir.opusgtx.com/press-releases/detail/311/rexahn-pharmaceuticals-announces-stockholder-approval-of-all-proposals-required-for-merger-with-ocuphire-pharma 2024-10-21T13:39:32-04:00 https://ir.opusgtx.com/press-releases/detail/310/ocuphire-to-participate-in-upcoming-virtual-healthcare-investor-conferences-in-september 2024-10-21T13:40:21-04:00 https://ir.opusgtx.com/press-releases/detail/305/rexahn-and-ocuphire-enter-into-definitive-merger-agreement 2024-10-21T13:39:33-04:00 https://ir.opusgtx.com/press-releases/detail/309/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-diabetic-retinopathy-and-diabetic-macular-edema-from-apexian-pharmaceuticals 2024-10-21T13:40:23-04:00 https://ir.opusgtx.com/press-releases/detail/308/ocuphire-pharma-announces-results-from-two-phase-2-clinical-studies-of-nyxol-eye-drops 2024-10-21T13:40:23-04:00 https://ir.opusgtx.com/press-releases/detail/304/rexahn-to-explore-strategic-alternatives 2024-10-21T13:39:33-04:00 https://ir.opusgtx.com/press-releases/detail/307/ocuphire-pharma-announces-completion-of-the-first-of-two-phase-2b-clinical-trials-for-nyxol-eye-drops 2024-10-21T13:40:23-04:00 https://ir.opusgtx.com/press-releases/detail/303/rexahn-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-update-on-rx-3117-development 2024-10-21T13:39:33-04:00 https://ir.opusgtx.com/press-releases/detail/306/ocuphire-pharma-raises-over-5-million-to-complete-multiple-late-phase-2-clinical-trials 2024-10-21T13:40:23-04:00 https://ir.opusgtx.com/events/detail/20260420-2026-annual-meeting-of-stockholders 2026-03-25T13:58:54-04:00 https://ir.opusgtx.com/events/detail/20260325-rbc-capital-markets-global-ophthalmology-conference 2026-03-23T19:05:18-04:00 https://ir.opusgtx.com/events/detail/20260311-citizens-life-sciences-conference 2026-03-11T15:56:00-04:00 https://ir.opusgtx.com/events/detail/20260310-leerink-global-healthcare-conference 2026-03-10T14:55:17-04:00 https://ir.opusgtx.com/events/detail/20260227-the-macula-society-annual-meeting 2026-02-25T17:33:03-05:00 https://ir.opusgtx.com/events/detail/20260115-j-p-morgan-2026-healthcare-conference 2025-12-17T15:57:55-05:00 https://ir.opusgtx.com/events/detail/20251202-piper-sandler-37th-annual-healthcare-conference 2025-11-20T17:08:53-05:00 https://ir.opusgtx.com/events/detail/20251021-chardans-9th-annual-genetic-medicines-conference 2025-10-14T22:07:41-04:00 https://ir.opusgtx.com/events/detail/20251016-eyecelerator-american-academy-of-ophthalmology-aao 2025-10-29T18:02:06-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-010758/0001140361-26-010758.pdf 2026-03-23T16:08:37-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-010757/ny20063680x2_def14a.htm 2026-03-23T16:07:14-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0000905148-26-001384/form4.html 2026-03-18T16:18:34-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0000905148-26-001382/form4.html 2026-03-18T16:18:13-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0000905148-26-001381/form4.html 2026-03-18T16:17:34-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0000905148-26-001380/form4.html 2026-03-18T16:17:20-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001974078-26-000120/primary_doc.html 2026-03-16T16:55:31-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-009408/ny20067725x1_s3.htm 2026-03-13T16:56:59-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-009254/ny20063680x1_pre14a.htm 2026-03-12T17:01:38-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-009247/ef20060643_10k.htm 2026-03-12T17:03:34-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-008621/ef20067388_8k.htm 2026-03-10T07:17:56-04:00 https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-26-006176/ef20066083_form8k.htm 2026-02-19T16:03:17-05:00 https://ir.opusgtx.com/disclaimer https://ir.opusgtx.com/sitemap https://ir.opusgtx.com/accessibility-statement